Endocrine Abstracts

Inpatient hypoglycaemia is common and associated with adverse outcome during admission and post discharge. We investigated management of hypoglycaemia using the time to repeat (TTR) capillary blood glucose (CBG) measurement as a surrogate for engagement with clinical guidelines.Methods: Inpatient CBG data from 8 hospitals over a 7 y period were analysed. Primary care prescribing information was available, and admissions were associated with insulin or SU...

Objective: We aimed to test the utility of semantic analysis to predict all-cause mortality from free-text entries from both a national diabetes database, and an open source clinical dataset (MIMIC-III). We analysed text entries alone, in order to fully understand the potential of language analysis to predict outcome.Method: Diabetes dataset: An analysis period of 3 years was defined during which clinical text data were extracted. Mortality status at 1 y...

Introduction: C-peptide is frequently used in clinical practice to estimate insulin secretion, and guide need for future insulin treatment. Present practice is based on studies with small patient numbers.Aim: To explore the association between non-stimulated c-peptide and progression to insulin therapy in patients with diabetes.Patients and Methods: 1971 patients with c-peptide measurements were identified (February 2007–Decem...

Aim: To determine the association between recorded inpatient glycaemic variability and long-term mortality in patients with diabetes mellitus.Methods: Inpatient capillary blood glucose (CBG) readings from eight acute hospitals were included. Data was analysed from first admission within the dataset with >4 measured CBGs. 28 353 admissions were identified (24 181 type 2 DM, 4,172 type 1 DM). Matching parameters were: age, diabetes duration, admission ...

Background: Dapagliflozin was the first SGLT2 inhibitor licensed in UK to improve glycaemic control in type 2 diabetes. Whilst it has not been studied for use in combination with GLP1 agonists the modes of action of the two therapies suggest they would be a logical therapeutic combination. We aimed to evaluate clinical experience with this regimen.Methods: Observational retrospective data was collected from electronic patient records (SCI–diabetes) ...

Background: Dapagliflozin was the first SGLT2 inhibitor licensed in UK to improve glycaemic control in type 2 diabetes. The study aimed to assess impact of dapagliflozin on glucose, weight and BP and identify factors predictive of glycaemic response in a large cohort.Methods: Observational retrospective data collected on all patients prescribed dapagliflozin across primary and secondary care in two Scottish health board areas. HbA1c, weight, BP and conco...

Introduction: Hypophosphatasia (HPP) is a very rare systemic musculoskeletal disease characterised by low tissue non-specific alkaline phosphatase (ALP). The prevalence of HPP and its associated morbidity in an adult setting is unclear.Methods: A search for serum ALP results less than 36 IU/l within NHS Greater Glasgow and Clyde between 2017 and 2018 revealed 16 280 results. A further search for patients with two ALP <36 separated by 30 days or more ...

Introduction: Increased prevalence of diabetes is found in major psychosis, and poorer outcomes occur when both diagnoses co-exist. The aim of this study was to describe the association between total and cardiovascular mortality in people with both schizophrenia and diabetes, compared to diabetes alone.Materials and methods: Data was linked from the Glasgow Psychosis Clinical Information System (PsyCIS), the Scottish national diabetes database (SCI-Diabe...